Why is the Recce (ASX:RCE) share price in the red today?

The Recce (ASX: RCE) share price is in the red today despite the company releasing positive data from its latest drug trials.

| More on:
A woman with black afro hair and wearing a white t-shirt shrugs and purses her lips

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has spent today in the red despite the company releasing positive data from anti-infective drug trials against bacterial sinusitis in mice.

It seems shareholders weren't excited by the results, with the Recce share price dropping from its opening price of 98 cents to close at 97 cents.

Recce is a drug discovery and development business that produces synthetic antibiotics to address the global health challenge of antibiotic-resistant superbugs. 

Recce report shows positive sinusitis fight

Recce's data is from a large trial involving a total of 12 groups of 10 mice each. The study was performed to reveal the efficacy of a new anti-infective formulation, called RECCE 111 (R111), against Streptococcus pneumoniae bacterial sinusitis.

Streptococcus pneumoniae, a gram-positive bacterium (a type of bacterium cell wall), is a leading cause of bacterial pneumonia and meningitis in the United States and a common cause of bloodstream infections, also known as sepsis, ear and sinus infections.

Recce 111 is the title for a wholly-owned experimental compound produced by Recce Pharmaceuticals in-house. The testing showed significant antibacterial capability with no abnormalities detected in any of the 12 groups of mice, with most of the groups administered the drug twice daily.

This news on its own wasn't enough to send the Recce share price flying today.

Three groups were treated with varying intranasal doses twice daily. These groups showed a significant dose-dependent antibacterial effect when compared to early infection. However, the average efficacy of these doses may be why shareholders appeared uninterested in the company today.

Three groups of mice were treated with varying intravenous doses of up to 1,000 milligrams per kilogram of weight. In contrast, the remaining group of three were treated with intravenous doses up to 250 milligrams per kilogram of weight. Both of these studies revealed relatively similar results.

Azithromycin was the positive control in the study given twice daily at 200 mg/kg and showed a bactericidal effect.

What Recce management said

Recce CEO James Graham said the results were strong for a range of Recce research targets.

We're continually excited by the potential of Recce's anti-infective compounds and are encouraged by these positive indications. Moreover, this further enhances the breadth of Recce's synthetic polymer platform.

Recce share price snapshot

The Recce share price has offered a one-year return of 276% but is down 3.5% this week, 8.5% this month and 9% this year to date. At its current price, Recce has a market capitalisation of $167.7 million.

Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »